Develops RNA editing therapeutics for neurodevelopmental and liver diseases.
Dec 2025Revenue €15.9M/yrExpenses €59.4M/yr
No trendCash runway ≈ 1.7 years from Dec 2025
Figures by year
When will ProQR Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was €15.9M and expenses €59.4M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | €15.9M | €59.4M | −€43.4M |
| Dec 2024 | €18.9M | €49.4M | −€30.5M |
| Dec 2023 | €6.51M | €38.4M | −€31.9M |
| Dec 2022 | €3.59M | €68.8M | −€65.2M |
| Dec 2021 | €1.33M | €58.5M | −€57.2M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.